ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Pepperstone

Trade Now

Pepperstone
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P ASX 200
8,509.40
0.73%
S&P ASX All Technology
4,016.30
1.26%
Brent Oil
71.89
0.00%
US Dollar vs AUD
1.54481
0.02%
Bitcoin
95,826.40
-0.04%
Pepperstone
Advertisement
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. AMEX
  6. Can Fite BioPharma Ltd (CANF)

  7. Can Fite BioPharma Ltd (CANF) News

CANF

Can Fite BioPharma (CANF)

Can Fite BioPharma Ltd
Date:
Sort by:
 Showing the most relevant articles for your search:AMEX:CANF
DateTimeSourceHeadlineSymbolCompany
15/11/202408:48Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]AMEX:CANFCan Fite BioPharma Ltd
11/11/202423:00GlobeNewswire Inc.Can-Fite Achieves Milestone with First Patient Dosing in Pancreatic Cancer Phase IIa Clinical TrialAMEX:CANFCan Fite BioPharma Ltd
04/11/202423:09Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
04/11/202423:08GlobeNewswire Inc.Can-Fite anti-Obesity Drug Namodenoson Received Patent Allowance in AustraliaAMEX:CANFCan Fite BioPharma Ltd
19/10/202400:23Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
19/10/202400:06GlobeNewswire Inc.Significant Positive Results from Osteoarthritis Clinical Study in Dogs Treated with PiclidenosonAMEX:CANFCan Fite BioPharma Ltd
09/10/202422:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
09/10/202422:00GlobeNewswire Inc.FDA Grants Orphan Drug Designation to Can-Fite’s Namodenoson for Pancreatic CancerAMEX:CANFCan Fite BioPharma Ltd
07/10/202422:00GlobeNewswire Inc.Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on October 29AMEX:CANFCan Fite BioPharma Ltd
24/09/202421:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
24/09/202421:00GlobeNewswire Inc.Projected Income of $325M to Can-Fite Over the Next 10 Years After Vetbiolix Exercised its Option and Licensed Piclidenoson for Veterinary OsteoarthritisAMEX:CANFCan Fite BioPharma Ltd
16/09/202421:07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
16/09/202421:00GlobeNewswire Inc.Can-Fite: Pancreatic Carcinoma Phase IIa Clinical Study with Namodenoson Received Regulatory Authorization from the Israeli Ministry of HealthAMEX:CANFCan Fite BioPharma Ltd
09/09/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:CANFCan Fite BioPharma Ltd
07/09/202406:30Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]AMEX:CANFCan Fite BioPharma Ltd
06/09/202414:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessAMEX:CANFCan Fite BioPharma Ltd
31/08/202406:18Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
31/08/202406:18Edgar (US Regulatory)Form F-3 - Registration statement by foreign private issuersAMEX:CANFCan Fite BioPharma Ltd
31/08/202406:16Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementAMEX:CANFCan Fite BioPharma Ltd
31/08/202406:15Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]AMEX:CANFCan Fite BioPharma Ltd
29/08/202422:46Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
29/08/202422:15GlobeNewswire Inc.Can-Fite Reports First Half 2024 Financial Results & Progress in Two Pivotal Phase III Clinical StudiesAMEX:CANFCan Fite BioPharma Ltd
12/08/202420:45Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
09/08/202420:07Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
09/08/202409:01GlobeNewswire Inc.Can-Fite Announces Exercise of Warrants for Approximately $5.0 Million in Gross ProceedsAMEX:CANFCan Fite BioPharma Ltd
29/07/202421:03Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
29/07/202421:00GlobeNewswire Inc.Can-Fite Provides Namodenoson Patent UpdateAMEX:CANFCan Fite BioPharma Ltd
17/07/202421:00GlobeNewswire Inc.Join Can-Fite’s Exclusive Live Investor Webinar and Q&A Session on August 8AMEX:CANFCan Fite BioPharma Ltd
11/07/202421:05Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]AMEX:CANFCan Fite BioPharma Ltd
11/07/202421:00GlobeNewswire Inc.Can-Fite Applies for FDA Orphan Drug Designation for Namodenoson in the Treatment of Pancreatic CancerAMEX:CANFCan Fite BioPharma Ltd
 Showing the most relevant articles for your search:AMEX:CANF

Your Recent History

SPI
SP500
S&P 500
NYSE
MCD
McDonalds
ASX
ANZ
Australia And New Zealan...
NYSE
JPM
JP Morgan Chase
ASX
XAO
Australian SE All Ordina...
NYSE
KO
Coca Cola
NASDAQ
NVDA
NVIDIA
ASX
XFL
S&P ASX 50
NYSE
NKE
Nike
ASX
ORG
Origin Energy
FTSE
UKX
FTSE 100
FX
AUDJPY
AUD vs Yen
CCOM
SILVER
SILVER
ASX
QBE
QBE Insurance
ASX
SUN
Suncorp
NASDAQ
TSLA
Tesla
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Australia
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved

BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for ASX Level 1 & 2

1 year 40%, 2 years 40% and *3 years 60%

*Across 3 years $1958.40 only $783.36